Skip to main content

Table 1 Characteristics of patients taking ZDV/3TC scored tablets (n = 541)

From: Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand

  N (%) / median [IQR]
Country
 UK/Ireland 96 (18)
 Other European countriesa 152 (28)
 Russia 90 (17)
 Thailand 203 (38)
Male gender 250 (46)
Ethnic group
 White 151 (28)
 Black African 104 (19)
 Asian and other 236 (44)
 Unknown 50 (9)
Mode of HIV infection
 MTCT 450 (83)
 Other 13 (2)
 Unknown 78 (14)
Ever AIDS event 145 (27)
Median age at ART start (years) 6 [2, 9]
Median age at ZDV/3TC scored tablet start (years) 10 [7, 13]
ART experienced (≥1 ART drug) before ZDV/3TC scored tablets 429 (79)
Median duration on ART before ZDV/3TC scored tablet start (years) 4 [1, 6]
Exposure to ZDV and 3TC before starting ZDV/3TC scored tablets 327 (60)
Median VL at ZDV/3TC start (log10c/mL) 1.7 [1.6, 3.3]
Median CD4 cell count ZDV/3TC start (cells/mm3) 660 [416, 972]
Median CD4% at ZDV/3TC start 28 [19, 34]
Median time on ZDV/3TC scored tablets (months)b 30 [17, 56]
Time to discontinuation of ZDV/3TC (n = 233)
 <1 month 11 (5)
 1–<6 months 29 (12)
 6–<12 months 32 (14)
 ≥12 months 161 (69)
Reasons for stopping tablets (n = 233)
 Treatment failure (immunological/virological) 42 (18)
 Toxicity/side effects 17 (7)
 Death 7 (3)
 Non-compliance 9 (4)
 Patient’s wish/decision 7 (3)
 Co-morbidity 1 (0)
 Physician’s decision 3 (1)
 Simplified treatment available 73 (31)
 Better safety profile 1 (0)
 Unknown 73 (31)
  1. aOther European countries are Belgium, Greece, Italy, Poland, Portugal, Romania, Spain and Sweden
  2. bFor those still on ZDV/3TC at the last follow-up